Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of
Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse. Hematopoietic stem cell (HSC) transplantation remain the gold standard of consolidation, to maintain a durable response. In t
| Condition(s) | Malignant Hemopathy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse. Hematopoietic stem cell (HSC) transplantation remain the gold standard of consolidation, to maintain a durable response. In this situation, allograft with hematopoietic stem cells donor aims at producing Graft-versus-Tumor effect, by producing a new immune system, reproducing anti-tumoral immunity. However, all hemopathies do not have the same sensibility. Nowadays, mechanisms underlying this phenomenon remain poorly understood. Indeed, few data precisely document the expression of immunological checkpoints and other biomarkers in the context of allogeneic HSC transplantation, particularly their im |
| Who can participate | Inclusion Criteria: * Adult patient, over 18 years of age, suffering from a malignant hemopathy (without exception), * Patient for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated, * Signed informed consent, * Patient covered by a social security scheme. Exclusion Criteria: * Allogeneic hematopoietic stem cell transplantation from cord blood or haplo-identical transplant, * Allogeneic transplant with post-transplant cyclophosphamide treatment, * Allograft with sequential conditioning. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Locations | Saint-Etienne, France |
| Start date | 2022-05-25 |
| NCT ID | NCT04517656 |
| Official listing | https://clinicaltrials.gov/study/NCT04517656 |